European Hospital Georges Pompidou, 20, rue Leblanc, 75015 Paris, France.
Target Oncol. 2012 Mar;7 Suppl 1:S17-24. doi: 10.1007/s11523-011-0189-2. Epub 2012 Jan 17.
Biosimilars are equivalent drugs for other biotechnological drugs for which patent has expired. These biopharmaceuticals are often looked upon as simple copies of parent drugs whose goal is solely to potentially generate costs savings. The expansion of available drugs is a subject of attention, criticism and quarrels, often related to a lack of product knowledge. These drugs are copies but need scientific development that must meet many strict rules. Many questions arise in connection with the marketing of several biosimilar drugs in the field of hematopoietic growth factors of white and red cells. Many of them should be discussed.
生物类似药是指已过专利期的其他生物技术药物的等效药物。这些生物制药通常被视为原药的简单复制品，其目标仅仅是可能节省成本。可用药物的扩张是一个备受关注、批评和争议的话题，这往往与产品知识的缺乏有关。这些药物是复制品，但需要进行科学开发，必须符合许多严格的规定。在白细胞和红细胞的造血生长因子领域，有许多与几种生物类似药的营销相关的问题，其中许多问题都需要讨论。
